The present invention is directed to novel PD-1-targeted IL-l5/Ra-Fc fusion proteins comprising an IL-l5/IL-l5Ra Fc-fusion protein and a PD-l antigen binding domain. The PD-1-targeted IL-l5/Ra-Fc fusion proteins can be administered to a patient to treat cancer.
展开▼